Literature DB >> 17036056

Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector.

S Myhre1, P Henning, O Granio, A S Tylö, P A Nygren, S Olofsson, P Boulanger, L Lindholm, S-S Hong.   

Abstract

In this study, a prototype Adenovirus type 5 (Ad5) vector deleted of the fiber knob domain and carrying an Affibody molecule as the targeting ligand showed decreased susceptibility to human pre-existing antibodies. This vector, Ad5/R7-Z(taq)Z(taq), has short fibers carrying seven shaft repeats, a non-native trimerization signal and an affibody molecule (Z(taq)) reactive to Taq polymerase. Ad5/R7-Z(taq)Z(taq) could be specifically targeted to 293 cells stably expressing membrane-bound anti-Z(taq) idiotypic affibody called Z(ztaq) (293Z(ztaq)). Sera from 50 blood donors were analyzed for neutralization activity (NA) against the parental Ad5/Fiwt vector and knobless Ad5/R7-Z(taq)Z(taq) on 293Z(ztaq) cells. Twenty-three sera had NA titers (> or =1:64) against Ad5/Fiwt (46%) and only two against Ad5/R7-Z(taq)Z(taq) (4%). Characterization of sera with NA titers showed that the knob domain is one of the targets of the antibodies. Neutralization assays using sera pre-adsorbed on knob and hexon proteins showed that the NA of the sera was carried mainly by anti-knob and anti-hexon antibodies, but in certain sera the anti-hexon antibodies represent the major population of the neutralizing antibodies (NAbs). Our results suggested that a combination of knob deletion and hexon switching could be an effective strategy for Ad vectors to better evade the anti-Ad NAbs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036056     DOI: 10.1038/sj.gt.3302875

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  12 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

Review 2.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

Review 3.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

Review 4.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

Review 5.  Polymeric oncolytic adenovirus for cancer gene therapy.

Authors:  Joung-Woo Choi; Young Sook Lee; Chae-Ok Yun; Sung Wan Kim
Journal:  J Control Release       Date:  2015-10-23       Impact factor: 9.776

6.  Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo.

Authors:  Julia Reetz; Berit Genz; Claudia Meier; Bhavani S Kowtharapu; Franziska Timm; Brigitte Vollmar; Ottmar Herchenröder; Kerstin Abshagen; Brigitte M Pützer
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

7.  Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation.

Authors:  Michael O Alberti; Justin C Roth; Mourad Ismail; Yuko Tsuruta; Edward Abraham; Larisa Pereboeva; Stanton L Gerson; David T Curiel
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

8.  Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction.

Authors:  Stéphanie Corjon; Gaëlle Gonzalez; Petra Henning; Alexei Grichine; Leif Lindholm; Pierre Boulanger; Pascal Fender; Saw-See Hong
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

9.  Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.

Authors:  Andrea Mohr; Mark Lyons; Laura Deedigan; Tina Harte; Georgina Shaw; Linda Howard; Frank Barry; Tim O'Brien; Ralf Zwacka
Journal:  J Cell Mol Med       Date:  2008-03-28       Impact factor: 5.310

Review 10.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.